Abstract：Objective: To investigate the effect of Singulair combined with Symbicort on elderly patients with stable chronic obstructive pulmonary disease (COPD). Methods: Prospectively, 198 elderly patients with stable COPD admitted to our hospital between January 2019 and May 2021 were selected for the study, and all patients were divided into groups A, B and C using simple random grouping, and were given cisplatin (montelukast sodium tablets), cisplatin duplex (budesonide formoterol inhaler), cisplatin + cisplatin duplex, respectively, on the basis of conventional symptomatic management for 12 weeks. The respiratory function, inflammatory response, disease control status, clinical efficacy and incidence of adverse effects were compared before and after the intervention in the three groups. Results: In all three groups, FEV1, FVC, FEV1/FVC ratio and PaO2 were significantly higher than before the intervention, while PaCO2, sputum neutrophils, eosinophil ratio, IL-8, MPO level and total CAT questionnaire score were significantly lower than before the intervention (P<0.05). When comparing between groups, the differences in FEV1, FVC, FEV1/FVC, PaO2, PaCO2, sputum neutrophils, eosinophil ratio, IL-8, MPO level and total CAT questionnaire score before and after intervention were significantly higher in group C than in groups A and B during the same period, and the differences in FEV1/FVC, PaO2, PaCO2, sputum neutrophil ratio, IL-8, MPO level and total CAT questionnaire score before and after intervention were significantly higher in group B. The overall effective rate of group C was 95.5%, which was significantly higher than that of group A (74.2%) and group B (80.3%) (P<0.017). All patients did not suffer from serious complications such as liver and kidney function damage, cardiac arrhythmia and skeletal muscle tremor, etc. The difference in the incidence of each complication among the three groups was not statistically significant (P>0.05), and all patients recovered after symptomatic treatment without affecting the treatment process. Conclusion: Singulair combined with Symbicort could significantly improve the symptoms, respiratory function and airway inflammation of elderly patients with stable COPD, which is safe, effective and worthy of clinical application.
张启龙, 马艳梅, 马红红, 高隆. 顺尔宁联合信必可都保对老年稳定期慢性阻塞性肺疾病患者的应用效果分析[J]. 河北医学, 2022, 28(6): 1002-1006.
ZHANG Qilong, MA Yanmei, MA Honghong, et al. Analysis of the Efficacy of Singulair in Combination with Symbicort in Elderly Patients with Stable COPD. HeBei Med, 2022, 28(6): 1002-1006.
2022, Vol. 28 
冀公网安备13080202000677号